Pasithea Therapeutics Corp.

KTTA

Pasithea Therapeutics Corp.

KTTA

Insider Sentiment (TTM):

Last Purchase:2026-06-17Last Sale:2025-05-12Shares Purchased (TTM):299,999Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:12,818,618Shares Outstanding:24,337,812Institutional Ownership Pct.:52.67%

Earnings Market Reaction:

Filing Date:2026-08-14Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	46	50	55	4	7	5	7	9	8	12	16	20
Available For Sale Securities Debt Securities Curr…	-	-	-	-	-	-	-	-	-	-	-	0
Restricted Cash Current	0	0	0	0	-	-	-	-	-	-	-	-
Prepaid Expense Current	2	2	1	1	1	1	0	0	1	1	0	1
Other Assets Current	0	0	0	0	0	0	0	0	0	0	0	0
Assets Current	48	53	56	6	9	6	7	10	9	13	17	21
Property Plant And Equipment Net	-	-	-	-	0	0	0	0	0	0	0	0
Operating Lease Right Of Use Asset	-	-	-	-	-	-	-	-	-	0	0	0
Finite Lived Intangible Assets Net	3	4	4	-	-	-	7	-	-	-	-	8
Intangible Assets Net Excluding Goodwill	-	-	3	7	7	7	7	7	8	8	8	-
Goodwill	-	-	-	1	1	1	1	1	1	1	1	1
Assets	52	56	60	14	17	15	16	19	18	22	26	31
Liabilities And Stockhold…
Liabilities Current
Accounts Payable And Accrued Liabilities Current	2	1	1	1	2	1	1	1	1	2	3	2
Operating Lease Liability Current	-	-	-	-	-	-	-	-	-	0	0	0
Liabilities Current	2	1	5	1	2	2	1	1	1	2	3	2
Liabilities Noncurrent
Derivative Liabilities Noncurrent	-	-	-	0	0	0	-	-	-	-	-	0
Warrants And Rights Outstanding	0	0	0	-	-	-	0	0	0	0	0	-
Liabilities Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Liabilities	2	2	5	1	2	2	1	1	1	3	3	2
Stockholders Equity
Operating Lease Liability Noncurrent	-	-	-	-	-	-	-	-	-	-	-	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	128	128	125	72	72	66	64	64	59	59	59	59
Accumulated Other Comprehensive Income Loss Net Of…	0	0	0	0	0	-	-0	-0	-0	-0	-0	-0
Retained Earnings Accumulated Deficit	-78	-73	-70	-60	-57	-53	-50	-46	-43	-39	-35	-30
Stockholders Equity	50	55	55	12	15	13	15	18	16	20	23	28
Liabilities And Stockholders Equity	52	56	60	14	17	15	16	19	18	22	26	31
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	5	5	5	5	5	5	5	5	5	5	5	5
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0.7
Common Stock Shares Authorized	500	500	100	100	100	100	100	100	100	100	100	495
Common Stock Shares Issued	33	25	23	7	7	3	1	1	1	1	1	1
Shares Outstanding	33	25	23	7	7	3	1	1	1	1	1	1

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-25.00%	-29.49%	-43.08%	-	-	-	-	-	-	-	-	-
2025	2.90%	-14.98%	-18.93%	12.38%	12.52%	15.79%	60.74%	69.27%	22.48%	-3.50%	-2.10%	-30.07%
2024	-15.79%	-23.68%	-24.81%	-13.61%	10.10%	-21.65%	-16.96%	-8.77%	-34.50%	10.40%	-23.52%	-37.12%
2023	-	-	-	-	-	-	-3.23%	12.90%	4.84%	-	-	-
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	26.25	35.40	11.35	4.02	4.97	3.84	6.58	14.81	6.20	5.35	6.34	10.16
Quick Ratio	24.91	34.17	11.19	3.08	4.22	3.45	6.31	14.32	5.79	4.93	6.26	9.68
Working Capital	46.41M	51.24M	51.49M	4.15M	6.90M	4.53M	6.25M	9.12M	7.25M	10.73M	14.06M	18.73M
Leverage & Debt
Debt to Equity	0.04	0.03	0.09	0.12	0.12	0.13	0.09	0.05	0.09	0.13	0.12	0.08
Interest Coverage TTM	-	-	-	-	-	-	-	-	-	-143.42	-129.30	-120.36
Debt Ratio	0.04	0.03	0.08	0.10	0.11	0.11	0.08	0.04	0.08	0.11	0.10	0.07
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01
Per Share Metrics
Diluted EPS TTM	-0.66	-0.81	-2.91	-1.81	-2.39	-6.15	-12.69	-15.11	-15.71	-15.62	-13.01	-12.74
Free Cash Flow Per Share TTM	-0.50	-0.70	-2.16	-1.24	-1.67	-5.72	-12.70	-14.15	-14.30	-13.39	-10.51	-11.22
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-	-	-	-	-	-	-	-	-	-	-	-6,178.91%
Net Profit Margin TTM	-	-	-	-	-	-	-	-	-	-	-	-6,659.90%
Growth Metrics
Net Revenue Growth (1Y)	-	-	-	-	-	-	-	-100.00%	-100.00%	-100.00%	-100.00%	-2.09%
Net Income Growth (1Y)	58.22%	45.03%	46.91%	-14.46%	-17.88%	-16.44%	-12.89%	-1.60%	-3.63%	2.42%	14.53%	69.35%
EPS Growth (1Y)	-72.19%	-86.82%	-77.10%	-88.00%	-84.81%	-60.61%	-2.51%	18.56%	20.67%	28.08%	17.87%	78.69%
Valuation Metrics
P/E TTM	-0.78	-0.92	-0.44	-0.40	-0.30	-0.21	-0.25	-0.36	-0.32	-0.46	-0.57	-0.75
P/B TTM	0.33	0.33	0.16	0.45	0.27	0.22	0.23	0.32	0.33	0.38	0.39	0.43
P/S TTM	-	-	-	-	-	-	-	-	-	-	-	50.17
Market Cap	16.53M	18.06M	9.07M	5.45M	4.07M	2.87M	3.45M	5.66M	5.28M	7.56M	9.08M	12.08M
Enterprise Value	-29.23M	-32.44M	-29.31M	1.23M	-3.15M	-2.47M	-3.47M	-3.70M	-2.69M	-4.45M	-7.25M	-7.51M
Calculated Values
Free Cash Flow TTM	-16.05M	-16.94M	-15.21M	-9.20M	-9.43M	-12.66M	-13.92M	-14.77M	-14.91M	-13.96M	-12.89M	-14.11M
Net Debt	-45.77M	-50.50M	-38.38M	-4.22M	-7.22M	-5.34M	-6.92M	-9.36M	-7.97M	-12.01M	-16.33M	-19.58M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-17Purchase

Owner: Coastlands, Capital Lp

Title: -

Shares: 100,000

Price/Share: $0.53

Value: $53,000.00

Shares Owned: 3,835,035

Relationship: TenPercentOwner

Ownership: Indirect

2025-11-28Purchase

Owner: Marques, Tiago

Title: Chief Executive Officer

Shares: 33,333

Price/Share: $0.75

Value: $24,999.75

Shares Owned: 73,334

Relationship: Director,Officer

Ownership: Direct

2025-11-28Purchase

Owner: Dumesnil, Simon

Title: -

Shares: 33,333

Price/Share: $0.75

Value: $24,999.75

Shares Owned: 35,833

Relationship: Director

Ownership: Direct

2025-11-28Purchase

Owner: Steinman, Lawrence

Title: -

Shares: 133,333

Price/Share: $0.75

Value: $99,999.75

Shares Owned: 199,691

Relationship: Director

Ownership: Direct

2025-05-12Sale

Owner: Marques, Tiago

Title: Chief Executive Officer

Shares: 960

Price/Share: $0.83

Value: $796.80

Shares Owned: 40,001

Relationship: Director,Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-17	Coastlands, Capital Lp	TenPercentOwner	-	Indirect	Purchase	100,000	0.53	$53,000.00	3,835,035	4
2025-11-28	Marques, Tiago	Director,Officer	Chief Executive Officer	Direct	Purchase	33,333	0.75	$24,999.75	73,334	4
2025-11-28	Dumesnil, Simon	Director	-	Direct	Purchase	33,333	0.75	$24,999.75	35,833	4
2025-11-28	Steinman, Lawrence	Director	-	Direct	Purchase	133,333	0.75	$99,999.75	199,691	4
2025-05-12	Marques, Tiago	Director,Officer	Chief Executive Officer	Direct	Sale	960	0.83	$796.80	40,001	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

52.67%

Inst. Shares: 12,818,618

Shares Outstanding: 24,337,812

2025-12-31

183.36%

Inst. Shares: 12,892,082

Shares Outstanding: 7,031,050

2025-09-30

7.74%

Inst. Shares: 576,068

Shares Outstanding: 7,443,577

2025-06-30

5.32%

Inst. Shares: 300,344

Shares Outstanding: 5,641,251

2025-03-31

3.56%

Inst. Shares: 78,704

Shares Outstanding: 2,211,207

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	12,818,618	24,337,812	52.67%
2025-12-31	12,892,082	7,031,050	183.36%
2025-09-30	576,068	7,443,577	7.74%
2025-06-30	300,344	5,641,251	5.32%
2025-03-31	78,704	2,211,207	3.56%
2024-12-31	77,162	1,096,082	7.04%
2024-09-30	9,086	1,044,144	0.87%
2024-06-30	29,996	1,043,312	2.88%
2024-03-31	30,055	1,042,479	2.88%
2023-12-31	216,340	1,226,600	17.64%
2023-09-30	209,130	1,258,050	16.62%
2023-06-30	285,388	1,306,401	21.85%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Pasithea Therapeutics Corp. (KTTA) — SEC Financial Statements & Analysis

Pasithea Therapeutics Corp. (KTTA) is a pharmaceutical preparations company, incorporated in DE. Pasithea Therapeutics Corp. trades on Nasdaq as: KTTA, KTTAW. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Pasithea Therapeutics Corp. reported a -100.00% year-over-year revenue growth, a Debt-to-Equity ratio of 0.04x, a Price-to-Sales (P/S) ratio of 50.17x (TTM), a Price-to-Book (P/B) ratio of 0.33x (TTM), at a market cap of $16.53M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -100.00%
Debt To Equity: 0.04x
P/S TTM: 50.17x
P/B TTM: 0.33x
Market Cap: $16.53M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Pasithea Therapeutics Corp. in?

Pasithea Therapeutics Corp. (KTTA) operates in the Pharmaceutical Preparations industry.

What is KTTA's market cap?

Pasithea Therapeutics Corp. (KTTA) has a market capitalization of $16.53M as of 2026-06-30.

What exchange does KTTA trade on?

Pasithea Therapeutics Corp. (KTTA) trades on the Nasdaq.

Where is Pasithea Therapeutics Corp. incorporated?

Pasithea Therapeutics Corp. is incorporated in DE.